Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study - Concepedia

Concepedia

Publication | Closed Access

Once-Daily Abacavir/Lamivudine and Ritonavir-Boosted Atazanavir for the Treatment of HIV-1 Infection in Antiretroviral-Naïve Patients: A 48-Week Pilot Study

28

Citations

18

References

2008

Year

Richard Elion, Edwin DeJesus, Michael Sension, Daniel Berger, William Towner, Gary Richmond, Marty St. Clair, Linda Yau, Belinda Ha

HIV Clinical Trials

Abstract

ABC/3TC and ATV-RTV QD is an effective and well-tolerated regimen in ART-naïve patients through 48 weeks, with a modest impact on fasting lipids.

References

	Year	Citations

Page 1